Feb 1 2011
Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that it has received approval from Health Canada for the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures. The system has already been in use in Europe and the United States treating liver and lung tumors via a small 1.8 mm needle puncture of the skin. This groundbreaking treatment allows physicians to apply precise microwave energy to remove unwanted tissue masses whilst avoiding the risks associated with longer, more invasive surgical interventions.
The Accu2i pMTA system is now cleared in Europe, the United States, and Canada and it delivers 2.45 GHz of power to ablate tumors of the liver and lung. The design consists of a 1.8 mm diameter closed water cooled needle that allows physicians to ablate up to five centimeter lesions in minutes. The system is unique in that it uses specialized patented microwave antenna designs that achieve the very high levels of microwave energy deposition into tissue needed to quickly and effectively coagulate unwanted areas of soft tissue.
"The Health Canada approval builds on the momentum we experienced in 2010 with the CE mark and FDA clearance of the Accu2i pMTA system," said Stuart McIntyre, CEO of Microsulis Medical Limited. "We are pleased to have received this approval from Health Canada for the pMTA system so physicians can begin to offer this game changing treatment options for patients in Canada with liver or lung tumors."
Source: Microsulis Medical Limited
AI algorithm accurately detects early-stage metabolic-associated steatotic liver disease